Table 1.

NLRP3 inflammasome inhibitors in experimental AMI

Name(s)	Method(s)	Finding(s)	Reference(s)
Colchicine	0.1 mg/kg ip daily for 7 days to the mouse starting before ischemia in the nonreperfused AMI model	Smaller scar, reduced adverse remodeling, and heart failure and improved survival	8, 54
N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[a ]heptalen-7yl] acetamide	0.4 mg/kg ip 25 min before reperfusion in a model of transient I/R	Reduced infarct size and fibrosis in the chronic setting
Glyburide derivative;	100 mg/kg ip before surgery in a reperfused AMI model	Reduced infarct size and improved LV function	84, 86, 127
16673-34-0	100 mg/kg ip after ischemia in a model of nonreperfused AMI	Improved cardiac remodeling and LV dysfunction
5-chloro-2-methoxy-N-[2-(4-sulfamoyl-phenyl) ethyl] benzamide	100 mg/kg ip up to 60 min after reperfusion	Reduced infarct size at 24 h
MCC950	3–6 mg/kg iv 15 min before reperfusion and again after 24 h and following 5 days in the pig balloon angioplasty inflation ischemia model	Reduced infarct size; improved cardiac remodeling and prevention of LV dysfunction	138
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4-(2-hydroxypropan-2-yl)furan-2-sulfonamide; N-[[(1,2,3,5,6,7-hexahydro-S-indacen-4-yl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)-2-furansulfonamide
BAY 11-7082	Treatment (dose not specified) before ischemia or before reperfusion in I/R models in mouse and rat	Reduced infarct size; preserved cardiac function	71
3-[(4-methyl- phenyl)-sulfonyl]-(2E)-propenenitrile
INF4E	50 μM in an ex vivo myocardial ischemia model 20 min before ischemia	Reduced infarct size at 60 minReduced infarct size	88
ethyl 2-((2-chlorophenyl)(hydroxy)methyl)acrylate
OLT1177 (dapansutrile)	6–600 mg/kg ip before, or up to 60 min after, reperfusion in the mouse surgical coronary artery ligation model		128
3-(methanesulfonyl) propanenitrile

AMI, acute myocardial infarction; I/R, ischemia-reperfusion; LV, left ventricular; NLRP3, NOD-like receptor protein 3.